J7353 Anacaulase-bcdb 8.8% gel 1 g
Also known as: Xeloderm, anacaulase, enzymatic debridement
Topical application of anacaulase-bcdb (serine protease), 8.8% gel, 1 gram, for enzymatic wound debridement.
In Plain Language
wound debridement gel; dead tissue removal
Clinical Context
Used for selective enzymatic debridement of necrotic tissue in wounds, ulcers, and burns without affecting viable tissue.
RVU Information
CPT J7353 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J7353?
CPT J7353 (Anacaulase-bcdb 8.8% gel 1 g) is a J Codes (Drugs) code. Topical application of anacaulase-bcdb (serine protease), 8.8% gel, 1 gram, for enzymatic wound debridement.
How is J7353 administered?
CPT J7353 is administered by a healthcare provider, typically via injection or infusion. Used for selective enzymatic debridement of necrotic tissue in wounds, ulcers, and burns without affecting viable tissue. It is used by Wound Care, Dermatology, Surgery.
When is CPT J7353 used?
Used for selective enzymatic debridement of necrotic tissue in wounds, ulcers, and burns without affecting viable tissue.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.